Clinical Trials

Finding the cure is the answer; working together is the first step. 

Take the step to join a clinical trial for leukodystrophy therapies, if you are able! Improved therapies and a cure will only be found if researchers have patients involved. With rare diseases, it is even more key to have every patient able to be involved providing assistance to the research process. Sometimes patients or caregivers are concerned about joining clinical trials because of the fear of “being a guinea pig to science.” Patients involved in clinical trials are not “guinea pigs.” They are human beings, and the researchers who rely on the patients for their participation are deeply grateful. Patients who are involved in clinical trials are first in line to receive potentially life changing, and lifesaving, treatments. Results of clinical trials also impact the future of every single person who faces a leukodystrophy diagnosis. The ULF hopes you will consider being part of clinical trials, as more become available for the leukodystrophies. 

Please refer to the link below for the most up to date information on what clinical trials are recruiting or in progress. You will need to reach out to the facilitator of the trial directly in order to determine eligibility for the trial. 

---

ULF Partner Clinical Trials

Below are the clinical trials that the ULF is proud to promote on behalf of our partners. If you see a clinical trial below that you believe you are eligible for, please reach out to Keely Haag, Director of Operations, at keely@ulf.org. She will get you in touch with our contact for that trial. Please note: the ULF can only assist with connecting you to the trials associated with our partners below. If there is a trial on ClinicalTrials.gov that you are interested in, you will need to reach out directly to the facilitators of the trial. 

	The Embolden Study is evaluating the safety and effects of a study drug on gross motor function (the abilities required to control the large muscles of the body for walking, running, sitting, crawling, and other activities) in children ages six months to six years old with late infantile MLD. This clinical research study has the potential to impact families in the future, and your child’s participation may contribute to bringing forth a treatment option for other children diagnosed with MLD. Many times, children in the toughest situations display the most strength. And your little warrior is no exception. If your child has been diagnosed with metachromatic leukodystrophy, the Embolden Study may be an option. Talk to your child’s doctor and visit www.EmboldenStudy.com for more information.
	OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD) OTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progressive demyelination affecting the central and peripheral nervous system. The aim of this clinical study is to assess the pharmacodynamic effect and long-term clinical efficacy and safety of OTL-200 in Late Juvenile MLD patients.
	Bluebird Bio, inc.: ALD-104, Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
	Minoryx (Europe): An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral X-linked Adrenoleukodystrophie (cALD).
	Children's Hospital of Philadelphia: Once enrolled, we will work closely with each family to explore additional resources that may be of interest, including opportunities through their local GLIA-CTN study site. Note that we are actibely recruiting participants for other GLIA-CTN natural history studies, as well, including 4H, Alexander Disease, ALD/AMN, AGS, MLD, and PMD.
	Study to Evaluate Patients With Cerebrotendinous Xanthomatosis The study is made up of two cohorts: a randomized double-blind crossover (placebo withdrawal with rescue) study among patients ≥ 16 years of age (adult cohort) and an open-label dose titration study among pediatric patients ≥1 month and <16 years of age (pediatric cohort)
	Cerebrotendinous Xanthomatosis (CTX) Prevalence Study This is an observational, multicenter study to determine the prevalence of Cerebrotendinous Xanthomatosis (CTX) in patient populations diagnosed with early-onset idiopathic bilateral cataracts. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were seen at each study site prior to that site's initiation, or by entering care at the site while the site is participating in the trial.
	The REPLACE Registry for Cholbam®/Kolbam® (Cholic Acid) This is a prospective, observational, non-interventional patient registry designed to document long term safety and clinical outcomes for 10 years in patients treated with Cholbam/Kolbam, including those who have been using Cholbam/Kolbam and those who start Cholbam/Kolbam treatment at enrollment.